Exceptional Response of Metastatic Chromophobe Renal Cell Carcinoma to Vascular Endothelial Growth Factor (VEGF) Inhibitors: Should Increased VEGF-C Expression Be Used to Guide Treatment?

There is sparse literature demonstrating effective treatments for metastatic chromophobe renal cell carcinoma (ChRCC). The tyrosine kinase inhibitor (TKI) sunitinib selectively inhibits the VEGF pathway and it is a standard care for metastatic clear cell renal cell carcinoma (ccRCC), although data s...

Descripción completa

Detalles Bibliográficos
Autores principales: Bruinius, Jacob W., Dykema, Karl J., Noyes, Sabrina L., Teh, Bin Tean, Lane, Brian R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2019
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6949673/
https://www.ncbi.nlm.nih.gov/pubmed/31956465
http://dx.doi.org/10.1155/2019/2479823

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6949673/
https://www.ncbi.nlm.nih.gov/pubmed/31956465
http://dx.doi.org/10.1155/2019/2479823

Ejemplares similares